NEW YORK (GenomeWeb) – Nuclea Biotechnologies announced today that it has partnered with Aelan Cell Technologies to develop, validate, and commercialize novel biomarker tests and companion diagnostics, with a focus on cancer, metabolic disorders, neurodegeneration, aging, and aging-related disorders.

Nuclea said that the arrangement would combine its expertise in proteomics with Aelan's genomics know-how. Specifically, Nuclea will provide protein analysis of the human stem cells used as models for the tests, while Aelan will provide DNA and mRNA analysis.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.